US stock · Healthcare sector · Medical Instruments & Supplies
Company Logo

Baxter International Inc.

BAXNYSE

45.16

USD
-1.52
(-3.26%)
After Hours Market
23.34P/E
13Forward P/E
1.06P/E to S&P500
22.766BMarket CAP
2.44%Div Yield
Upcoming Earnings
9 Feb
Shares Short
1/13/23
7.05M
Short % of Float
1.58%
Short % of Shares Outs.
1.40%
% Held by Insiders
0.20%
% Held by Institutions
90.05%
Beta
0.59
PEG Ratio
3.98
52w. high/low
89.70/43.25
Avg. Daily Volume
5.48M
Return %
Stock
S&P 500
1 year
(45.83)
(7.99)
3 years
(50.28)
23.80
5 years
(28.74)
56.27
Scale: |
High
Low
38.85
25.75
33.13
24.69
33.61
21.86
33.95
25.83
37.43
26.61
40.52
34.11
41.99
36.03
43.44
32.18
50.16
34.06
66.18
44.06
78.38
61.05
89.93
64.13
95.19
69.10
88.32
73.12
89.70
49.00
53.12
43.25
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
15.94
17.49
19.76
20.70
21.77
24.42
25.75
28.10
30.76
18.29
18.61
19.45
20.84
22.32
22.93
25.12
29.33
Earnings per share
2.14
2.65
3.22
3.63
2.41
3.91
4.22
3.71
4.61
1.78
9.09
1.32
3.04
1.97
2.17
2.52
(4.71)
FCF per share
2.55
2.50
2.50
3.12
3.46
3.26
3.53
3.08
2.43
1.35
1.71
2.22
2.65
2.77
2.28
2.91
1.49
Dividends per share
0.56
1.09
0.87
1.04
1.17
1.25
1.46
1.88
2.02
1.67
0.49
0.58
0.70
0.83
0.93
1.04
1.13
CAPEX per share
0.81
1.07
1.53
1.67
1.63
1.69
2.11
2.81
3.50
1.67
1.32
1.17
1.28
1.37
1.39
1.46
1.42
Book Value per sh.
9.63
10.74
9.97
11.85
11.13
11.57
12.59
15.59
14.98
16.23
15.18
16.80
14.60
15.49
17.07
17.83
16.19
Comm.Shares outs.
651
644
625
607
590
569
551
543
542
545
546
543
534
509
509
509
503
Avg. annual P/E ratio
- -
11.2
10.3
8.1
11.2
7.5
7.5
10.1
8.5
21.0
4.8
43.9
22.9
40.3
38.7
32.0
23.3
P/E to S&P500
- -
0.6
0.5
0.1
0.5
0.5
0.5
0.6
0.5
1.1
0.2
1.9
0.9
1.7
1.0
1.1
1.1
Avg. annual div. yield
- -
3.7%
2.6%
3.6%
4.3%
4.2%
4.6%
5.0%
5.2%
4.5%
1.1%
1.0%
1.0%
1.0%
1.1%
1.3%
1.9%
Revenue (m)
10,378
11,263
12,348
12,562
12,843
13,893
14,190
15,259
16,671
9,968
10,163
10,561
11,127
11,362
11,673
12,784
14,740
Operating margin
17.7%
19.2%
20.8%
22.9%
16.6%
21.2%
19.9%
17.5%
16.2%
4.5%
7.1%
11.9%
14.4%
15.6%
13.8%
13.4%
(12.5)%
Depreciation (m)
575
581
631
638
685
670
712
823
1,005
759
800
761
785
789
823
890
1,314
Net profit (m)
1,396
1,707
2,014
2,205
1,420
2,224
2,326
2,012
2,497
968
4,965
717
1,624
1,001
1,102
1,284
(2,376)
Income tax rate
19.9%
19.3%
17.8%
19.0%
24.5%
19.7%
19.5%
21.1%
20.2%
8.2%
(0.2)%
40.5%
3.7%
(4.2)%
14.1%
12.3%
12.9%
Net profit margin
13.5%
15.2%
16.3%
17.6%
11.1%
16.0%
16.4%
13.2%
15.0%
9.7%
48.9%
6.8%
14.6%
8.8%
9.4%
10.0%
(15.6)%
Working capital (m)
3,360
3,743
3,513
3,807
3,948
3,793
4,501
4,098
4,309
6,046
3,830
4,442
3,083
4,273
5,078
4,636
4,102
Long-term debt (m)
2,567
2,664
3,362
3,440
4,363
4,749
5,580
8,126
7,606
3,935
2,779
3,509
3,473
4,809
6,287
17,671
16,607
Equity (m)
6,272
6,916
6,229
7,191
6,567
6,585
6,938
8,463
8,120
8,846
8,290
9,124
7,794
7,882
8,689
9,077
5,535
ROIC
13.3%
15.7%
18.1%
18.2%
11.4%
16.5%
15.5%
10.7%
12.7%
6.9%
39.4%
5.4%
13.4%
7.5%
7.4%
5.0%
(7.0)%
Return on capital
12.6%
14.6%
16.9%
16.6%
11.6%
15.2%
14.8%
10.5%
12.2%
5.5%
32.4%
7.6%
11.4%
5.9%
7.2%
5.0%
(7.0)%
Return on equity
22.3%
24.7%
32.3%
30.7%
21.6%
33.8%
33.5%
23.8%
30.8%
10.9%
59.9%
7.9%
20.8%
12.7%
12.7%
14.1%
(42.9)%
Plowback ratio
73.9%
58.8%
72.9%
71.3%
51.5%
68.1%
65.4%
49.2%
56.1%
6.0%
94.6%
56.1%
76.8%
57.7%
57.1%
58.7%
123.9%
Div.&Repurch./FCF
(25.3)%
158.6%
162.2%
97.5%
105.0%
123.4%
117.4%
115.7%
124.9%
123.6%
59.9%
73.1%
199.9%
120.2%
84.0%
76.4%
- -
Capital Structure
27 Oct · 2022 | Q3
All numbers in millions
Total liabilities
$ 22,386
Total assets
$ 27,965
Long-term debt
$ 16,607
Cash and equiv.
$ 1,601
Goodwill
$ 6,639
Retained earnings
$ 14,015
Common stock
504
Enterprise Value
$ 37,772
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
3,335
3,730
2,951
Receivables
1,896
2,077
2,629
Inventory
1,653
1,916
2,453
Other
619
1,083
455
Current assets
7,503
8,411
8,872
Acc. Payable
892
1,043
1,246
Debt due
642
517
639
Other
1,696
1,773
2,351
Current liabilities
3,230
3,333
4,236
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
9.52%
4.93%
0.24%
Cash flow
27.61%
6.76%
0.38%
Earnings
16.52%
28.69%
43.50%
Dividends
12.05%
13.93%
2.23%
Book value
4.47%
0.31%
3.54%
Insider Trading
Type
Shares
Date
Mason Jeanne K
Exempt
19,826
01/17/23
Mason Jeanne K
Exempt
19,826
01/17/23
Mason Jeanne K
Exempt
19,825
01/17/23
Mason Jeanne K
Sale
59,477
01/17/23
Mason Jeanne K
Exempt
59,477
01/17/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
2,802
2,718
2,972
3,181
11,673
2021
2,946
3,098
3,226
3,514
12,784
2022
3,707
3,746
3,773
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.65
0.48
0.70
0.33
2.16
2021
0.59
0.59
0.88
0.47
2.52
2022
0.14
0.50
(5.83)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.22
0.22
0.25
0.25
0.93
2021
0.25
0.24
0.28
0.28
1.04
2022
0.28
0.28
0.29
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
CEO:
Mr. Jose Almeida
Full-time employees:
60,000
City:
Deerfield
Address:
1 Baxter Pkwy
IPO:
May 15, 1961
Website:
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.